Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor κB

Giant cell tumor (GCT) of bone is an aggressive skeletal tumor characterized by localized bone resorption. MicroRNA-16-5p (miR-16-5p) has been reported to be downregulated in lesions of patients with GCT, but little is known about its role in GCT. To explore the underlying function of miR-16-5p in GCT, we first detected its expression in patients with GCT. The results showed that osteoclast formation increased, whereas miR-16-5p expression considerably decreased with the severity of bone destruction. Furthermore, we found that miR-16-5p expression considerably decreased with the progression of receptor activator of nuclear factor-κB ligand- (RANKL-) induced osteoclastogenesis. Functionally, miR-16-5p mimics significantly reduced RANKL-induced osteoclast formation. However, treatment with an inhibitor of miR-16-5p significantly promoted osteoclastogenesis. These findings reveal that miR-16-5p inhibits osteoclastogenesis and that it may represent a therapeutic target for giant cell tumor of bone.

Download Full-text

The values of receptor activator nuclear Kappa-B ligand expression in stage III giant cell tumor of the bone

Indian Journal of Orthopaedics ◽

10.4103/ortho.ijortho_153_17 ◽

2018 ◽

Vol 52 (1) ◽

pp. 31

Author(s):

WanFaisham Wan Ismail ◽

SabrinaAbdul Ghani ◽

MdSalzihan Md. Salleh ◽

Sahran Yahaya ◽

ZawawiMuhamad Syahrul Fitri

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Cell Tumor ◽

Stage Iii ◽

Receptor Activator ◽

Ligand Expression

Download Full-text

Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study

Journal of Orthopaedic Research® ◽

10.1002/jor.22873 ◽

2015 ◽

Vol 33 (8) ◽

pp. 1205-1211 ◽

Cited By ~ 18

Author(s):

Irene Quattrini ◽

Serena Pollino ◽

Laura Pazzaglia ◽

Amalia Conti ◽

Chiara Novello ◽

...

Keyword(s):

Retrospective Study ◽

Giant Cell Tumor ◽

Giant Cell ◽

Bone Remodeling ◽

Cell Tumor ◽

Nuclear Factor ◽

Prognostic Role

Download Full-text

Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Giant Cell Tumor of Bone

American Journal Of Pathology ◽

10.1016/s0002-9440(10)64942-5 ◽

2000 ◽

Vol 156 (3) ◽

pp. 761-767 ◽

Cited By ~ 169

Author(s):

Lin Huang ◽

JiaKe Xu ◽

David J. Wood ◽

Ming H. Zheng

Keyword(s):

Gene Expression ◽

Giant Cell Tumor ◽

Giant Cell ◽

Cell Tumor ◽

Receptor Activator ◽

Osteoprotegerin Ligand

Download Full-text

Correction to: The Values of Receptor Activator Nuclear Kappa-B Ligand Expression in Stage III Giant Cell Tumor of the Bone

Indian Journal of Orthopaedics ◽

10.1007/s43465-021-00404-7 ◽

2021 ◽

Author(s):

Sabrina Abdul Ghani ◽

Wan Faisham Wan Ismail ◽

Md. Salzihan Md. Salleh ◽

Sahran Yahaya ◽

Muhamad Syahrul Fitri Zawawi

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Cell Tumor ◽

Stage Iii ◽

Receptor Activator ◽

Ligand Expression

Download Full-text

Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab

Case Reports in Oncological Medicine ◽

10.1155/2015/626741 ◽

2015 ◽

Vol 2015 ◽

pp. 1-5

Author(s):

Natalia M. P. Fraile ◽

Diego Toloi ◽

Ceci O. Kurimori ◽

Adriana R. B. Matutino ◽

Alberto Codima ◽

...

Keyword(s):

Giant Cell Tumor ◽

Giant Cell ◽

Stromal Cells ◽

Giant Cells ◽

Cell Tumor ◽

Significant Activity ◽

Receptor Activator ◽

Endovascular Approach ◽

Nuclear Factor Kb ◽

Recent Demonstration

Giant cell tumor of bone (GCT) is a rare, locally aggressive neoplasm characterized by the presence of giant cells with osteoclast activity. Its biology involves the overexpression of theReceptor Activator of Nuclear Factor kB Ligand(RANKL) by osteoclast-like giant cells and tumor stromal cells, which has been shown to be an actionable target in this disease. In cases amenable to surgical resection, very few therapeutic options were available until the recent demonstration of significant activity of the anti-RANK-ligand monoclonal antibody denosumab. Here we present a case of a patient with advanced GCT arising in the spine, recurring after multiple resections and embolization. Following initiation of denosumab, which resulted in unequivocal clinical improvement, computed tomography of the chest done for reassessment purposes revealed an intratumoral pseudoaneurysm by erosion of the aorta, further corrected by endovascular approach and stent placement. Patient had an unremarkable recovery from the procedure and continued benefit from therapy with denosumab and remains on treatment 24 months after the first dose.

Download Full-text